| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NMI |
| Uniprot No | Q13287 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 62-202aa |
| 氨基酸序列 | EDIPETKMKFLSVETPENDSQLSNISCSFQVSSKVPYEIQKGQALITFEKEEVAQNVVSMSKHHVQIKDVNLEVTAKPVPLNSGVRFQVYVEVSKMKINVTEIPDTLREDQMRDKLELSFSKSRNGGGEVDRVDYDRQSGS |
| 预测分子量 | 51.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NMI重组蛋白的3篇参考文献及简要摘要：
1. **《N-myc downstream-regulated gene 1 (NDRG1) is expressed in macrophages and functions as a negative regulator of cell proliferation》**
*作者：Chen Y, et al.*
摘要：研究通过重组NMI蛋白发现其在巨噬细胞中高表达，并通过抑制STAT3信号通路调节细胞增殖和炎症反应，提示其在免疫调控中的作用。
2. **《Recombinant NDRG1 protein inhibits tumor growth by blocking c-Myc signaling in triple-negative breast cancer》**
*作者：Liu X, et al.*
摘要：利用重组NMI蛋白在乳腺癌模型中验证其通过结合c-Myc蛋白抑制肿瘤生长，为靶向治疗提供实验依据。
3. **《Expression and purification of functional NDRG1 recombinant protein for studying its interaction with membrane receptors》**
*作者：Wang H, et al.*
摘要：报道了NMI重组蛋白的高效原核表达系统及纯化方法，证实其与EGFR等膜受体结合，为结构功能研究奠定基础。
注：以上文献为示例性质，具体内容需根据实际研究补充。建议通过PubMed或Web of Science以“NMI recombinant protein”“NDRG1 expression”为关键词检索最新论文。
**Background of NMI Recombinant Protein**
N-myc and STAT interactor (NMI) is a protein that plays multifaceted roles in cellular signaling, particularly in immune regulation and cancer biology. Initially identified as an interactor of N-myc and STAT transcription factors, NMI modulates key pathways, including JAK-STAT, NF-κB, and TGF-β, by serving as an adaptor or scaffold protein. It contains coiled-coil domains that mediate protein-protein interactions, enabling its involvement in diverse processes such as cytokine signaling, cell cycle control, apoptosis, and DNA damage responses. NMI’s dual role in cancer—acting as a tumor suppressor or promoter depending on context—has sparked significant research interest, with studies linking its dysregulation to breast cancer, gliomas, and other malignancies.
Recombinant NMI protein is engineered using expression systems like *E. coli*, mammalian cells, or insect cells, ensuring high purity and activity for experimental applications. Bacterial systems offer cost-effective production but lack post-translational modifications, while eukaryotic systems preserve functional motifs critical for interaction studies. The recombinant protein is typically purified via affinity tags (e.g., His-tag) and validated through Western blotting, mass spectrometry, or functional assays.
In research, NMI recombinant protein is utilized to investigate its binding partners, signaling mechanisms, and structural properties. It aids in elucidating its context-dependent roles in tumorigenesis, immune evasion, and therapeutic resistance. Additionally, it serves as an antigen for antibody development, a tool for diagnostic assays, and a potential therapeutic agent in targeting NMI-associated pathways. As interest grows in personalized medicine, NMI recombinant protein remains a vital resource for unraveling its biological complexity and translational potential in disease management.
×
